but also incur substantial costs. Previous decision analyses (21-26) suggest that screening persons with colorectal cancer for the Lynch syndrome could be cost-effective. However, these analyses did not consider risk for gynecologic cancer, sex differences, or various age limits for screening. We hypothesized that these factors could strongly influence the effectiveness and cost-effectiveness of strategies to diagnose the Lynch syndrome.
We used decision analytic modeling to explore the clinical and economic consequences of competing strategies for identifying families with the Lynch syndrome, beginning with persons with newly diagnosed colorectal cancer. Our analyses focused on families in aggregate, female or male probands (see Glossary) with cancer, and female or male relatives without cancer. Screening for the Lynch syndrome was considered either for all persons with newly diagnosed colorectal cancer, regardless of age, or only for those younger than a certain age. Our purpose was to identify key variables that merit further clinical research and to inform public policy.
METHODS
Appendix 1 (available at www.annals.org) describes our decision analytic model and its data sources. Appendix 2 (available at www.annals.org) lists key concepts related to the Lynch syndrome.
Decision Analytic Model
Persons with newly diagnosed colorectal cancer entered a decision tree that modeled clinical or tumor-testing (see Glossary) strategies; up-front germline testing for mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, or PMS2) (5, 27); or a referent strategy of no active effort to diagnose the Lynch syndrome, which currently applies to most clinical settings. The population that entered the model included a small subpopulation of persons with the Lynch syndrome, which reflects the prevalence of the Lynch syndrome in the population modeled. A person with colorectal cancer and the Lynch syndrome was labeled a proband.
If a mutation was identified in a proband, relatives were offered single-site germline testing. The sequelae for female and male probands and relatives were modeled in separate Markov subtrees. The major clinical events were a first case of colorectal, endometrial, or ovarian cancer; metachronous colorectal cancer; screening and treatment complications; and death from cancer or other causes. We modeled varying levels of germline testing acceptance and adherence with preventive interventions and varying upper age limits for screening for the Lynch syndrome. A few families in our model had no identifiable mutation but were defined clinically as having the Lynch syndrome because of tumor features and a strong family pedigree that fulfilled the Amsterdam II criteria (28). In the base case, probands entered the model at a mean age of 48 years (15, 26, 29 -33 ) and relatives at a mean age of 25 years (34).
Glossary
BRAF mutation testing: Testing for the V600E mutation in the BRAF gene.
Presence of the mutation in tumors with absent MLH1 protein suggests sporadic cancer. Clinical criteria for the Lynch syndrome: Criteria based on family history and pathologic features that help to identify the Lynch syndrome. Includes the Amsterdam II criteria and revised Bethesda Guidelines. Germline testing: Testing of a blood sample to identify mutations by means of sequencing, deletion or duplication analysis, or rearrangement analysis. For the Lynch syndrome, germline testing may identify a mutation in a mismatch repair gene. Immunohistochemistry: Uses monoclonal antibodies against proteins to determine protein expression in tissue samples. For the Lynch syndrome, this shows the presence or absence of the protein products of mismatch repair genes. Microsatellite instability: A change of any length in a microsatellite (a DNA region with repeated patterns of base pairs) in a tumor compared with normal tissue, identified by using molecular testing. The presence of instability indicates impairment in the DNA replication and repair system, which may be caused by mutations in mismatch repair genes. Mismatch repair genes: MLH1 (mutL homolog 1), MSH2 (mutS homolog 2), MSH6 (mutS homolog 6), or PMS2 (postmeiotic segregation increased 2). Mutations in these genes result in impairment of the DNA replication and repair system. These mutations are the molecular cause of the Lynch syndrome. Prediction models: Models that use family history and pathologic features to calculate a probability that a person with colorectal cancer has the Lynch syndrome. Such models include MMRpredict, MMRpro, and PREMM(1,2,6). Proband: The first person with colorectal cancer and the Lynch syndrome discovered in a family, whose identification allows for subsequent identification and testing of family members. Tumor testing: Testing strategies to examine mismatch repair protein deficiency. Strategies include immunohistochemistry with or without selective BRAF testing and testing for microsatellite instability.
Preventive interventions were offered until age 75 years. Our simulation estimated outcomes until death or age 100 years.
Screening Strategies for the Lynch Syndrome
Tumors associated with the Lynch syndrome usually exhibit microsatellite instability (MSI) (see Glossary), and the absence of a mismatch repair gene product can be demonstrated with immunohistochemistry (IHC) (see Glossary) (6, 35), which can guide germline testing (34). Any strategy for identifying the Lynch syndrome consists of up to 4 phases (Appendix 2): an initial screening; further selection for germline testing, with possible tumor testing by IHC to guide germline testing; germline testing; and sitespecific germline testing in relatives at risk, including waves of testing for all relatives with a 50% risk for carrying a mutation (cascade testing).
The clinical criteria for the Lynch syndrome (see Glossary) used in the strategies in our model included the Amsterdam II criteria (36), which were developed to identify families with the classic Lynch syndrome; the revised Bethesda guidelines (37), which were developed to select tumors for testing; and mutation risk-prediction algorithms (MMRpro, PREMM[1,2,6], and MMRpredict; the strategy name implies application of the model with that name) (14, 38 -40). When clinical criteria were met or clinical algorithm scores suggested a greater than 5% probability of carrying a mutation, phase 2 IHC was performed and then germline testing was offered (for example, "MMRpro/IHC") or germline testing was offered directly (for example, "MMRpro/germline"). Immunohistochemistry was selected as the phase 2 tumor-based test on the basis of clinical practice, which acknowledges its unique attributes as a sensitive and specific test that can also guide which genes to target.
The tumor-testing strategies included MSI testing, IHC, MSI testing and IHC combined, and the addition of BRAF mutation testing (see Glossary) to IHC to detect sporadic loss of MLH1 function. When MSI or IHC results were abnormal, germline testing was offered.
When available, IHC results guided germline testing, with sequential testing of 1, 2, or more genes as required (34). In strategies without IHC, MLH1 and MSH2 were tested first and MSH6 and PMS2 were tested only if no mutation was found in the first 2 genes.
Clinical Management Programs
The intensive management program for persons with the Lynch syndrome included offering annual colonoscopy to probands after colorectal cancer diagnosis and to relatives with a germline mutation starting at age 25 years. For women, it also included annual gynecologic screening with transvaginal ultrasonography and endometrial sampling, starting at age 35 years, and prophylactic total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) at age 40 years, after completion of childbearing (34). Colonoscopic surveillance in the Lynch syndrome was assumed to decrease colorectal cancer incidence by 58% and mortality by 76% in the base case (7, 12). Because of the lack of proven benefit for gynecologic screening, this screening was assumed to incur costs but yield no benefit, which represents a bias against screening for the Lynch syndrome. We assumed that TAH-BSO eliminated the risk for endometrial and ovarian cancers (8). This intensive program was also offered to relatives whose status was uncertain because they had declined site-specific germline testing but who had a 50% risk for carrying a mutation; to probands in whom the Lynch syndrome was diagnosed clinically on the basis of Amsterdam II criteria and tumor features, despite the lack of a detectable mutation; and to their first-degree relatives. Persons whose tumors showed abnormal IHC or MSI results but who had normal germline testing results and did not meet Amsterdam II criteria were not offered intensive management of the Lynch syndrome, because such cases most likely represent false-positive results on tumor tests for the Lynch syndrome rather than false-negative results on germline tests. Sensitivity analyses were performed to address the consequences of screening for gastroduodenal cancer with upper endoscopy every 2 years without proven clinical benefit.
In our model, relatives proven to lack a mutation associated with the Lynch syndrome in their family were offered an average-risk colorectal cancer screening program of colonoscopy every 10 years starting at age 50 years (41). Colonoscopic screening was assumed to decrease colorectal cancer incidence and mortality by magnitudes suggested in the available literature and in previous decision analytic models (42) (43) (44) (45) . This program was also offered to probands with the Lynch syndrome who were misdiagnosed as having average risk, all of their relatives, and relatives of probands who declined germline testing (whose status was therefore unknown).
Costs
Costs were derived from published sources and Medicare schedules (Appendix 1).
Model Outputs and Cost-Effectiveness Analyses
Our principal model outputs were life expectancy and costs in 2010 U.S. dollars, discounted by 3% annually (46). Health state utilities are not available for the risk categories we used in the model, such as living with the knowledge that one carries a mutation or choosing not to test and living with uncertainty. Therefore, we did not estimate quality-adjusted life-years. Secondary outputs included number of cancer cases by type; deaths by cause; and, for illustrative purposes, undiscounted life-years.
Analyses were performed from the perspective of a third-party payer by using TreeAge Pro (TreeAge Software, Williamstown, Massachusetts) and Microsoft Excel 2003 (Microsoft, Redmond, Washington), in accordance with published recommendations (47, 48). We compared the various strategies and estimated incremental costeffectiveness ratios (ICERs), rounded to the nearest $100 (47, 48). Base-case analyses focused on families with a representative number of at-risk relatives, and the results reflect weighted averages for probands as well as mutationcarrying and noncarrier relatives. Because the base-case results represent a weighted average for female and male probands and relatives (in which probands and relatives entered the model at different ages), and these results depend on the number of relatives tested, we also present separate analyses that focus exclusively on female or male probands or relatives. In the base case, we assumed rates of acceptance of germline testing, adherence with screening recommendations, and risk-reduction operations that were consistent with the literature (Appendix Table 1 , available at www.annals.org).
Sensitivity Analyses
We performed 1-way sensitivity analyses and threshold analyses and examined varying levels of implementation of the strategies. Upper bounds for the potential benefit of the strategies were explored by assuming 100% acceptance of germline testing, screening, and risk-reducing operations. Institution of an upper age limit for screening for the Lynch syndrome was also explored, and ICERs that compare the more liberal with the more conservative age limits are presented.
We derived distributions of appropriate form (49) for input variables (Appendix Tables 1 and 2 , available at www.annals.org) and performed probabilistic sensitivity analyses (Monte Carlo simulation). Stabilization of variances was observed in runs of 500 to 1000 iterations; results for 1000 iterations are presented. These analyses yielded predictions about the optimal strategy under conditions of uncertainty, as a function of willingness to pay, which took incremental comparisons between all strategies into account and considered simple and extended dominance. Median estimates with 95% CIs and costeffectiveness acceptability curves (with the referent strategy as a comparator) are also presented.
Role of the Funding Source
Our study was funded by the National Institutes of Health. The funding source had no role in the design of the study; collection, analysis, or interpretation of the data; or approval of the manuscript.
RESULTS

Base Case
All strategies reduced cancer incidence and deaths and yielded more life-years per person than the referent strategy (Table 1 and Figure 1) . Accounting for incomplete acceptance of germline testing, screening, and prophylactic TAH-BSO, the various strategies reduced incidence of colorectal cancer by 5% to 29% and deaths by 7% to 42%, and incidence of endometrial and ovarian cancer and deaths by 1% to 6% ( Table 1) . Up-front germline testing in all probands was the most effective strategy.
Because of their sensitivity for mutations in each mismatch repair gene, the tumor-testing strategies as a group were more effective than the clinical criteria strategies as a group.
The more effective strategies tended to be more costly (Table 1 and Figure 1) . Assuming perfect implementation of all strategies, the tumor-testing strategies were more costly than the clinical criteria strategies, with an ICER of $117 000 per life-year gained for MSI plus IHC with BRAF testing compared with Bethesda/germline ( Table 1) . Up-front germline testing had an ICER of $293 000 per life-year gained.
Among the clinical criteria strategies, MMRpro/germline had an ICER of $41 400 per life-year gained and Bethesda/germline had an ICER of $50 200 per life-year gained. Among the tumor-testing strategies alone, IHC with BRAF testing had an ICER of $36 200 per life-year gained and MSI plus IHC with BRAF testing had an ICER of $108 000 per life-year gained.
Tumor-Testing Strategies Compared With Clinical Criteria Strategies
As the relative rate of implementation of clinical criteria strategies decreased compared with that of tumor-testing strategies, the tumor-testing strategies became progressively more cost-effective. The ICER of IHC with BRAF testing compared with MMRpro/germline was $49 400 per life-year gained when the clinical criteria under MMRpro/germline were not applied to 15% of persons with colorectal cancer who would otherwise have tumor testing.
Differential Effect on Probands and Relatives and the Effect of Sex
Testing showed greater potential benefits for women than for men. Table 2 illustrates the results for MMRpro/ germline, which had an acceptable ICER among the clinical criteria strategies, and IHC with BRAF testing, which emerged as the preferred strategy in probabilistic sensitivity analysis. The preferred strategies did not differ by sex.
The clinical benefit of all strategies accrued primarily to relatives with a mutation associated with the Lynch syndrome ( Table 2 ); in particular, the mean life expectancy of female relatives could be increased by up to 1.4 discounted life-years (4.5 undiscounted life-years) if they agreed to germline testing, screening, and TAH-BSO, depending on the strategy, with the most benefit achieved by up-front germline testing. The greater potential benefit for women was attributed to prevention of gynecologic cancer by TAH-BSO and to women having a longer life expectancy than men.
Every strategy had a substantially higher ICER when subsequent management tailored to risk was implemented only for a proband than when it was implemented only for a relative ( Table 2 ). The higher costs for women were attributed to the costs of gynecologic cancer screening and treatment and prophylactic TAH-BSO.
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Acceptance of Germline Testing and Preventive Interventions
The clinical benefit of all strategies increased as acceptance of germline testing and preventive interventions increased ( Table 2 and Appendix Table 3 , available at www .annals.org). In an optimal scenario that assumed universal acceptance of germline testing, screening, and prophylactic TAH-BSO at age 40 years after completion of childbearing, the strategies reduced colorectal cancer incidence by 8% to 47%, death from colorectal cancer by 12% to 68%, endometrial cancer incidence and death by 13% to 71%, and ovarian cancer incidence and death by 12% to 64%. The cost-effectiveness of the strategies improved as the rate of prophylactic TAH-BSO increased ( Table 2) .
Number and Age of Relatives Tested
The number of relatives tested per proband was a critical variable. All strategies became progressively more cost-effective as more relatives were tested. When 3 relatives were tested, all clinical criteria strategies, IHC, and IHC with BRAF testing cost less than $50 000 per life-year gained and the remaining tumor-testing strategies cost less than $60 000 per life-year gained compared with the referent strategy. When 4 relatives were tested, all clinical criteria and tumor-testing strategies cost less than $50 000 per life-year gained compared with the referent strategy.
The preferred strategy in probabilistic sensitivity analysis, IHC with BRAF testing, met a cost-effectiveness threshold of $100 000 per life-year gained compared with the referent strategy when 1 relative per proband was tested and a threshold of $50 000 per life-year gained when 3 relatives were tested (Figure 2) . When no relatives were tested, the cost of IHC with BRAF testing was approximately $140 000 per life-year gained (Figure 2) .
As the mean age of tested relatives increased, screening for the Lynch syndrome became progressively less cost-effective. Immunohistochemistry with BRAF testing met a cost-effectiveness threshold of $50 000 per life-year gained compared with the referent strategy at a mean age of 55 years but not 60 years (Appendix Table 3 ). IHC ϭ immunohistochemistry; MSI ϭ microsatellite instability. * Strategies are shown in order of increasing effectiveness. Total cohort size of 100 000 persons with a ratio of 8 relatives per proband, a germline testing acceptance rate of 0.52 by relatives, and the assumption that clinical criteria are determined for all probands. Cancer cases and deaths include those in probands and those in relatives with and without mutations associated with the Lynch syndrome. Results account for incomplete acceptance of germline testing, screening, and prophylactic surgery. For the clinical algorithm strategies that include IHC, IHC was reserved for those whose predicted probability of carrying a mutation was Ͼ5%. † Strategies that were dominated by simple or extended dominance are excluded.
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Upper Age Limit to Screen for the Lynch Syndrome
Instituting an upper age limit for screening for the Lynch syndrome decreased the size of the screened population while increasing the proportion of screened patients with the Lynch syndrome, but at the expense of excluding some older persons with the Lynch syndrome. This tradeoff resulted in increasing ICERs for higher compared with lower age limits ( Table 3) . For example, instituting an upper age limit of 50 years meant screening only 11% of all persons with newly diagnosed colorectal cancer, among whom the prevalence of the Lynch syndrome increased to 16%, and including 57% of all persons with the Lynch syndrome who presented with colorectal cancer (Table 3) .
Applying IHC with BRAF testing only to persons aged 50 years or younger who presented with colorectal cancer cost $27 900 per life-year gained compared with the referent strategy. Immunohistochemistry with BRAF testing had an ICER of $33 800 per life-year gained with an upper age limit of 60 years versus 50 years, $44 200 per life-year gained with an upper age limit of 70 years versus 60 years, and $88 700 per life-year gained with no age limit versus an upper age limit of 70 years ( Table 3) .
Additional 1-Way Sensitivity Analyses
As the prevalence of the Lynch syndrome decreased, the cost-effectiveness of all strategies worsened, but not dramatically. For instance, IHC with BRAF testing had an ICER of $55 700 per life-year gained compared with the referent strategy if the Lynch syndrome was assumed to account for 1% of colorectal cancer cases. Up-front germline testing achieved an ICER of $49 900 per life-year gained when the cost of germline testing decreased to $150 per gene tested and $99 700 per life-year gained when the cost of germline testing was $400 per gene tested.
Varying individual model inputs in extensive 1-way sensitivity analyses (Appendix Table 3 ) affected the ICERs between strategies but did not change the global conclusions suggested by our base-case results. Including the economic costs of screening for gastroduodenal cancer without assuming any clinical benefit did not affect the conclusions (Appendix Table 3 ).
Monte Carlo Simulation
At a threshold of $50 000 per life-year gained, IHC with BRAF testing was the optimal strategy in 53% of iterations, MMRpro/germline in 15% of iterations, no testing in 7% of iterations, and other strategies in fewer than 5% of iterations each. At a threshold of $100 000 per life-year gained, IHC with BRAF testing was the optimal strategy in 59% of iterations and MSI plus IHC with BRAF testing in 26% of iterations.
Compared with that in the referent strategy, a large proportion of the estimated cost-effectiveness ratios of most strategies were within traditional ranges of willingness to pay for a life-year gained (Figure 3 and Appendix Table  4 , available at www.annals.org). The median cost per lifeyear gained by IHC with BRAF testing compared with the referent strategy was $39 500 (95% CI, $18 900 to $77 000). When comparing 2 strategies, the one toward the right of the graph is more effective and the one toward the top of the graph is more costly. Tumor-testing strategies were more effective and more costly than clinical criteria strategies. The slope between 2 strategies represents the incremental cost-effectiveness ratio, with steeper slopes reflecting higher costs per life-year gained. The referent strategy reflects no active effort to diagnose the Lynch syndrome. IHC ϭ immunohistochemistry; MSI ϭ microsatellite instability.
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DISCUSSION
Our results suggest that the systematic application of strategies to diagnose the Lynch syndrome among patients with newly diagnosed colorectal cancer could provide substantial clinical benefits at acceptable costs. Such strategies are predicted to provide greater benefits to younger relatives without cancer than to older probands who present with colorectal cancer and greater benefits to women than men. The ultimate benefit and cost-effectiveness of any strategy are predicted to be highly dependent on the number of relatives per proband who have germline testing and take advantage of opportunities for cancer risk reduction.
The number of relatives tested per proband emerged as a key determinant of the cost-effectiveness of all strategies in our model. The reported rates of acceptance of germline testing by relatives at risk for the Lynch syndrome vary widely, ranging from 19% to 75% (50). Predictors of testing include family dynamics, personal beliefs, socioeconomic and educational factors, and comorbid conditions (51-53). Active involvement by dedicated professionals may increase testing rates (54, 55) , but optimal strategies for the diffusion and application of genomic information in families need to be designed. Whether physicians have a duty to warn relatives at risk is a question with clinical, ethical, and legal dimensions (56 -58) . Our analysis identifies the testing of at-risk relatives as an important focus for future research and public policy initiatives.
Although strategies based on clinical criteria performed relatively well in our model when universally applied, even low rates of failure to apply the clinical Among tumor-testing strategies, IHC with BRAF testing had an incremental cost-effectiveness ratio Ͻ$50 000 per life-year gained when 3 relatives but not when 2 relatives were tested per proband. IHC ϭ immunohistochemistry. IHC ϭ immunohistochemistry; TAH-BSO ϭ total abdominal hysterectomy and bilateral salpingo-oophorectomy. * The referent strategy reflects no active effort to diagnose the Lynch syndrome.
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Screening for the Lynch Syndrome www.annals.orgcriteria made tumor-testing strategies the preferred alternatives. Testing all tumors in pathology laboratories may be more feasible than ensuring widespread application of clinical criteria (32). Some medical centers have already adopted laboratory-based strategies (59, 60) . These approaches do not require clinicians to riskstratify patients or order specific tumor tests; however, they require clinicians to act on the basis of the results. Whereas discussions about genetic risk and genetic counseling are best handled in specialized clinics, the growing role of genetics in clinical medicine will require primary care clinicians to have ever-greater knowledge of its relevant principles and clinical applications.
Immunohistochemistry with BRAF testing, in which IHC tumor staining for mismatch repair gene products is followed by BRAF mutation testing of the tumor when MLH1 staining is absent, emerged as a preferred strategy in our model. This strategy focuses germline testing on the specific genes that probably harbor a mutation and can identify many cases of sporadic colorectal cancer with MLH1 promoter methylation, making germline testing more efficient. The slight gains in effectiveness by other tumor-testing strategies were achieved at high costs per life-year gained. However, the tradeoff between strategies depended on the specific combinations of test performance characteristics and costs assigned to each test. In settings in which IHC cannot be performed with high sensitivity and specificity (61), substituting or adding MSI testing may represent an effective and cost-effective alternative (62) .
Our exploration of an upper age limit for screening for the Lynch syndrome illustrates how to achieve a smaller screening population that includes a larger proportion of persons with the Lynch syndrome but at the expense of not capturing some older persons with the Lynch syndrome. On the basis of our results, screening for the Lynch syndrome up to age 70 years seems reasonable, and screening all persons with colorectal cancer (regardless of age) may also be acceptable, depending on society's willingness to pay. However, we did not directly address the demands for resources and the total budget effects of various age limits. These questions merit further research.
Our results are consistent with those of previous decision analyses (23) that suggest that screening for the Lynch syndrome could be cost-effective and that tumor-testing strategies based on IHC may be preferred. To our knowl- For any given strategy, a higher willingness to pay per life-year gained meant a higher probability that the strategy was considered cost-effective. All strategies are compared with the referent strategy. IHC ϭ immunohistochemistry; MSI ϭ microsatellite instability.
Original Research Screening for the Lynch Syndrome edge, our study is the first to address the critical issues of risk for gynecologic cancer, detailed exploration of the consequences for relatives compared with probands, sex differences, and upper age limits for screening. We explored strategies that target persons with cancer, rather than population-based screening of young adults (63), because such strategies are currently more viable. Future developments could influence the strategy of choice. As more families with the Lynch syndrome are identified, the cost-effectiveness of testing in unselected cases of colorectal cancer may diminish, but testing will probably remain cost-effective until most families with the Lynch syndrome have been identified. With substantial decreases in the cost of germline testing, up-front germline testing could become the preferred strategy. Given the fast pace of advances in DNA sequencing, the technical and up-front financial barriers to widespread germline testing for the Lynch syndrome and other diseases may soon be minor compared with the logistical and, in some cases, ethical and legal challenges.
The Lynch syndrome serves as a paradigm for personalized medicine. Our analysis illustrates some general principles. First, we found that the cost-effectiveness of screening for the Lynch syndrome depended on testing a minimum number of at-risk relatives per proband. For scenarios in which the potential benefits of germline testing do not extend predictably beyond probands, which may be the case for multigene testing, the benefits to probands may need to be substantially higher or the testing costs substantially lower than those in our simulation for germline testing to be cost-effective. Second, if disease-related risks are substantially lower than those we modeled, or if the ability to alter the disease course is poor, then the costs of testing may be unacceptably high compared with the benefits. Finally, applying upper age limits for screening may help optimize the balance among benefit, cost, and resource availability.
The strengths of our analysis include the consideration of multiple clinical and tumor-based strategies, incorporation of gynecologic cancer risk, prediction of global effects for families as well as differential effects for probands versus relatives and women versus men, acknowledgment of the comparatively favorable prognosis of colorectal cancer associated with the Lynch syndrome, consideration of an upper age limit for screening, and exploration of uncertainty by using probabilistic sensitivity analyses.
Our study has limitations. First, we did not model the risk for gastric, urologic, or other types of cancer because the benefits of screening for those types of cancer are uncertain. If such screening incurred substantial costs without clear benefit, the cost-effectiveness of searching for the Lynch syndrome would diminish. Second, we did not explicitly model testing of second-degree relatives who, on the sole basis of information about the proband, had a 25% risk for carrying a mutation; however, we assumed that cascade testing would clarify which of these persons actually had a 50% risk. Third, we did not incorporate health state utilities, because no data were available to inform the health states in which persons spend most of their life, characterized by the degree of knowledge of risk and acceptance of risk-reducing programs. Patient preferences among these health states could affect our results. Fourth, we did not include promoter methylation testing in addition to or as a substitute for BRAF mutation testing. Fifth, we did not apply value-of-information analysis to select variables for future research. Finally, our model does not consider adoption, uncertain paternity, lack of knowledge of family history, or the consequences of genetic variants of unknown significance.
In conclusion, widespread colorectal tumor testing to identify families with the Lynch syndrome could yield substantial clinical benefits at acceptable costs. Arguments have been advanced both in favor and against widespread tumor testing to identify probands with the Lynch syndrome (64, 65) . Because risk-reducing interventions can have a profound effect on persons who carry mutations associated with the Lynch syndrome, colorectal tumor testing should be viewed as a clinically viable and economically acceptable approach to identify families with the Lynch syndrome. For this approach to be cost-effective, it is imperative to overcome barriers to germline testing and riskreduction interventions among relatives at risk. 
APPENDIX 1: GENERAL MODEL DESCRIPTION
Persons with newly diagnosed colorectal cancer entered a decision tree that modeled the application of clinical criteria or predictive clinical algorithms; tumor testing; up-front germline testing for mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, or PMS2), which constitute the molecular basis of the Lynch syndrome (5, 27, 66); or a referent strategy of no active effort to diagnose the Lynch syndrome, which currently applies to most clinical settings (Appendix Figure) .
With all strategies, if a mutation was identified in a person with colorectal cancer, relatives with a 50% risk for carrying that mutation (such as first-degree relatives) were offered single-site germline testing. Thus, all persons with colorectal cancer due to the Lynch syndrome (probands) and their relatives were assigned to categories that reflected certainty or uncertainty regarding whether they carried a mutation associated with the Lynch syndrome and whether the Lynch syndrome had been clinically diagnosed despite the lack of a detectable mutation. The accuracy of the categorization was determined by the sensitivity and specificity of the strategy and the level of acceptance of germline testing. For the prediction algorithms, the sensitivities reflected detection of MLH1, MSH2, and MSH6 mutations.
Each of the categories for female and male probands and female and male relatives led to separate Markov subtrees with 1-year cycles that reflected the natural history of each scenario, with or without risk-reduction interventions. The major clinical events were the development of an initial or metachronous case of colorectal cancer, the development of endometrial or ovarian cancer, treatment of these cases of cancer, complications from treatments or preventive interventions, death from cancer, death related to preventive interventions, or death from other causes. The model was calibrated to reflect the age-specific and overall lifetime risk for these types of cancer in persons with or without the Lynch syndrome, as reflected by data from the SEER (Surveillance, Epidemiology, and End Results) program and published literature (Appendix Table 1 ) . Additional validation of the natural history of persons with the Lynch syndrome against independent sources was not possible, because all available data were used for calibration. However, the age-and cancer-specific risks illustrated in Appendix Table 1 lend confidence that our model calibration was appropriate. We accounted for the more favorable prognosis of colorectal cancer associated with the Lynch syndrome versus sporadic cancer (89) . On the basis of published literature that reported stage at diagnosis, as well as our previous models, persons with cancer detected by screening or surveillance had a more favorable prognosis than those whose cancer was diagnosed after symptomatic presentation.
We modeled varying levels of germline testing acceptance and adherence with preventive interventions. The development of other types of cancer associated with the Lynch syndrome, such as gastric or urinary tract cancer, was not explicitly modeled because of the lack of evidence to support preventive interventions for these types. Some families with the Lynch syndrome have no mutation that can be found with current methods (28), for which our model also accounted.
In the base case, probands entered the model at age 48 years, the mean age of onset of colorectal cancer in the Lynch syndrome (15, 26, 29 -33), and relatives entered the model at age 25 years, the age at which colorectal cancer surveillance is first recommended in the Lynch syndrome (34). Preventive interventions were offered until age 75 years. The Markov processes continued until age 100 years or death.
Base-case values and ranges for variables in the model were derived first from the recent meta-analysis and systematic review performed by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative (50). We also conducted supplementary literature searches for inputs that were not included in the EGAPP review (Appendix Tables 1 and 2 . We reviewed the titles and abstracts of articles that resulted from this search for information about testing validity, colorectal cancer risk, extracolonic cancer risk, adherence to screening and prevention services, acceptance of germline testing, risk for dying of cancer related to the Lynch syndrome, and cost data. Inputs derived from meta-analyses or systematic reviews were chosen when available. Cancer risk estimates were calculated on the basis of data from the SEER program (86) . We repeated our searches in March 2011 and found no major articles that provided data to challenge the assumptions in our analyses.
Costs were derived from published sources and Medicare professional and facility fee schedules (90, 91) and updated to 2010 U.S. dollars by using the medical component of the Consumer Price Index (95). Costs reflected all direct expenses associated with cancer care, screening for the Lynch syndrome, germline testing, preventive interventions, complications, and genetic counseling.
APPENDIX 2: KEY CONCEPTS
The existence of the entity now called the Lynch syndrome was first suggested by the observation of clusters of cancer cases, notably cases of colorectal cancer, diagnosed at a young age in certain families. Remarkable scientific progress has led to the identification of 4 DNA mismatch repair genes; mutations in these genes explain most cases of the Lynch syndrome. Colorectal tumors of patients with the Lynch syndrome often display characteristic features, including MSI and abnormal IHC results for mismatch repair genes.
Because the Lynch syndrome has associated clinical features, tumor characteristics, and germline mutations, various approaches can be considered for identifying persons with the syndrome. Strategies can be constructed that include 1 or more clinical criteria or risk-prediction algorithms, specific tumor tests, or germline testing. The search for persons with the Lynch syndrome can be considered to have 4 phases (Appendix Figure 1) .
First, some form of screening can be performed to include a greater proportion of persons with the Lynch syndrome in the population that will be further evaluated and may ultimately receive germline testing. One component of this screening may be to include only persons with newly diagnosed colorectal cancer. This already-selected group may be further screened by applying clinical criteria or risk-prediction algorithms, performing tumor testing, or instituting age criteria for screening. The cumulative initial screening could be complex if multiple criteria or tests are applied. The selected persons may proceed either to the second phase or directly to the third phase.
Second, the efficiency of germline testing can be enhanced by methods that narrow down the suspect mismatch repair genes in a particular person by inspecting tumor IHC results. If tumor IHC is itself the first screening test, then the first and second phases are the same.
Third, comprehensive testing of the relevant mismatch repair genes can be pursued, which involves full DNA sequencing; testing for deletions or insertions; and, in specific cases, testing for alterations in gene transcription regulatory regions.
Finally, when a specific mutation is detected in a person (for example, a man with early-onset colon cancer), site-specific DNA testing for this particular mutation can be offered to the person's first-degree relatives (for example, the man's brother and sister). If any of these relatives are found to carry the family's Lynch syndrome-associated mutation (for example, the brother), then their additional first-degree relatives can be offered germline testing (for example, the brother's daughter [the niece of the man with early-onset colon cancer]). This is referred to as cascade testing.
The Lynch Syndrome
The Lynch syndrome (sometimes referred to as hereditary nonpolyposis colorectal cancer [HNPCC] ) is a hereditary cancerpredisposition syndrome with elevated risks for colorectal, endometrial, ovarian, and other types of cancer. It is caused by a germline mismatch repair gene mutation that is inherited in an autosomal dominant manner (96, 97). Mutations in these genes result in mismatch repair protein deficiency, which affects the repair of DNA mismatches that occur during DNA replication. The propagation of such defects can result in abnormal cell growth.
Mutations in the following mismatch repair genes are known to cause the Lynch syndrome: MLH1 (mutL homolog 1), located on the short (p) arm of chromosome 3 at position 21.3; MSH2 (mutS homolog 2), located on the short (p) arm of chromosome 2 at position 21; MSH6 (mutS homolog 6), located on the short (p) arm of chromosome 2 at position 16; and PMS2 (postmeiotic segregation increased 2), located on the short (p) arm of chromosome 7 at position 22.2 (98).
Clinical Criteria and Prediction Models
Clinical criteria and prediction models may be used to target tumor or germline testing to identify persons with the Lynch syndrome. Clinical criteria include the Amsterdam II criteria, which are specific but not sensitive, and the revised Bethesda Guidelines (developed to select patients for tumor testing for MSI), which are more sensitive but less specific. Researchers have also developed several prediction models to estimate pretest gene mutation probability on the basis of several variables. The clinical criteria and the variables included in prediction models are described here.
Amsterdam II Criteria
The Amsterdam II criteria (36) require that at least 3 relatives, 1 of whom should be a first-degree relative of the other 2, have an HNPCC-associated cancer (colorectal cancer or endometrial, small bowel, ureter, or renal pelvic cancer); at least 2 successive generations should be affected; the cancer should be diagnosed in at least 1 of the relatives before age 50 years; familial adenomatous polyposis should be excluded in any patients with colorectal cancer; and tumors should be verified by pathologic examination.
Revised Bethesda Guidelines
According to the Bethesda Guidelines (37), tumors should be tested for MSI in the following situations: colorectal cancer diagnosed in a patient who is younger than 50 years; presence of synchronous, metachronous colorectal, or other HNPCCassociated tumors, regardless of age; colorectal cancer with the high level of MSI histology diagnosed in a patient who is younger than 60 years; colorectal cancer diagnosed in 1 or more firstdegree relatives with an HNPCC-related tumor, with 1 such case being diagnosed in a person younger than 50 years; or colorectal cancer diagnosed in 2 or more first-or second-degree relatives with HNPCC-related tumors, regardless of age.
MMRpredict
In the MMRpredict model (14), variables investigated as possible predictors of mismatch repair gene defects for the first stage include patient age at onset, sex, differentiation of the tumor (well, poor, or moderate), histology (standard mucinous), location of the tumor (right or left side), and other synchronous or metachronous tumors (no or yes). For first-and seconddegree relatives, variables include colorectal cancer (no, yes and diagnosed at age Ͻ50 years, or yes and diagnosed at age Ն50 years) and number of relatives with colorectal cancer, endometrial cancer (no, yes and diagnosed at age Ͻ50 years, or yes and diagnosed at age Ն50 years) and number of relatives with endometrial cancer, gastric cancer (no, yes and diagnosed at age Ͻ50 years, or yes and diagnosed at age Ն50 years) and number of relatives with gastric cancer, kidney cancer (no, yes and diagnosed at age Ͻ50 years, or yes and diagnosed at age Ն50 years) and number of relatives with kidney cancer, and any other cancer (no, yes and diagnosed at age Ͻ50 years, or yes and diagnosed at age Ն50 years) and number of relatives with any other cancer.
MMRpro
The MMRpro model (99) has the following inputs for each counselee and each first-or second-degree relative: exact relation to the counselee, colorectal cancer status (affected or unaffected) and age at diagnosis (in years) if affected, endometrial cancer status and age at diagnosis if affected, and current age or age at last follow-up if unaffected; result of MSI testing (instability present or not present) or IHC staining (loss of expression or present), if tumor is available; and result of previous germline testing of MLH1, MSH2, or MSH6 (positive or not found). Any input can be left unspecified if not available, with the exception of relation to the counselee.
PREMM(1,2,6)
In the PREMM(1,2,6) model (14, 39, 96, 97), the variables related to the proband are presence and age at diagnosis of colorectal cancer and number of cases (0, 1, 2, or more) of colorectal, endometrial, or other Lynch syndrome-related cancer (including cancer of the stomach, small intestine, pancreas, bile ducts, ovaries, urinary tract [kidney or ureter], brain [glioblastoma multiforme], or sebaceous glands). The variables related to the proband's family members are number of relatives with colorectal, endometrial, or other Lynch syndrome-related cancer; minimum age at diagnosis for each case of cancer in the family; presence of a relative with more than 1 Lynch syndrome-associated cancer; and degree of relationship to the proband (limited to first-or second-degree relative).
Tumor Testing
Any of the tumor-testing strategies described here may be used to examine mismatch repair protein deficiency.
IHC
Immunohistochemistry uses monoclonal antibodies against the MMR proteins to determine mismatch repair protein expression in tissue samples. Because the mismatch repair proteins form complexes (MLH1-PMS2 heterodimer and MSH2-MSH6 heterodimer), losing expression in 1 mismatch repair protein sometimes results in loss of expression in the partner protein (100). By showing loss of expression of specific proteins, IHC can guide germline testing. For example, IHC that shows loss of expression of MSH2 and MSH6 but not MLH1 and PMS2 would suggest germline testing of only the MSH2 gene first and then of the MSH6 gene if no mutations are found in MSH2 (101).
BRAF Testing
Sporadic loss of MLH1 protein expression may result from hypermethylation in the MLH1 gene promoter. To help distinguish between colorectal cancer associated with the Lynch syndrome and sporadic cancer, BRAF (V600E) mutation testing may be used. This mutation is frequently present in sporadic colorectal cancer with MLH1 hypermethylation. Therefore, tumors that show loss of MLH1 protein but neither BRAF V600E mutations nor hypermethylation are suspected of being associated with the Lynch syndrome (62).
Testing for MSI
Molecular testing of tumor samples for MSI indicates impairment in the DNA replication and repair system, which may have resulted from mismatch repair protein deficiency (62, 102) . Microsatellites are segments of DNA with repeated base pair patterns, such as TA repeated 20 times. In the presence of mismatch repair deficiency, daughter cells may harbor different repeat lengths at this microsatellite, such as 18 or 24 repeats. The National Cancer Institute recommends testing specific markers (such as D2S123, D5S346, D17S250, BAT25, and BAT26) to determine the presence of MSI, or "a change of any length due to either insertion or deletion of repeating units, in a microsatellite within a tumor when compared to normal tissue" (103). Instability is considered high-level when found in more than 30% of the markers and low-level when found in fewer than 30% of the markers. Microsatellites are considered stable in the absence of microsatellite alterations.
Germline Testing
Loss of mismatch repair protein expression may result from inherited mutations in the mismatch repair genes (MLH1, MSH2, MSH6, or PMS2). Germline testing of a blood sample can identify mutations through sequencing, deletion or duplication analysis, or rearrangement analysis. When a specific mutation is identified in a proband, subsequent germline testing can focus on identifying the same mutation in that single site among relatives. 
